ARCUS BIOSCIENCES INC (RCUS) Stock Price, Quote, News and Overview
NYSE:RCUS - New York Stock Exchange, Inc. - US03969F1093 - Common Stock - Currency: USD
RCUS Quote, Performance and Key Statistics
9.12
+0.5 (+5.8%)
The current stock price of RCUS is 9.12 USD. In the past month the price increased by 27.2%. In the past year, price decreased by -41.91%.
RCUS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.33 | 351.09B | ||
| AMGN | AMGEN INC | 13.55 | 151.20B | ||
| GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
| ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
| NTRA | NATERA INC | N/A | 21.18B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
| BIIB | BIOGEN INC | 7.81 | 18.10B |
Related stock screener links
About RCUS
Company Profile
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 627 full-time employees. The company went IPO on 2018-03-15. The firm has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The firm has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The firm is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). The company is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Company Info
ARCUS BIOSCIENCES INC
3928 Point Eden Way
Hayward CALIFORNIA 94545 US
CEO: Terry Rosen
Employees: 577
Phone: 15106946200
ARCUS BIOSCIENCES INC / RCUS FAQ
What is the stock price of ARCUS BIOSCIENCES INC today?
The current stock price of RCUS is 9.12 USD. The price increased by 5.8% in the last trading session.
What is the ticker symbol for ARCUS BIOSCIENCES INC stock?
The exchange symbol of ARCUS BIOSCIENCES INC is RCUS and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is RCUS stock listed?
RCUS stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for ARCUS BIOSCIENCES INC stock?
19 analysts have analysed RCUS and the average price target is 30.97 USD. This implies a price increase of 239.59% is expected in the next year compared to the current price of 9.12. Check the ARCUS BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ARCUS BIOSCIENCES INC worth?
ARCUS BIOSCIENCES INC (RCUS) has a market capitalization of 965.26M USD. This makes RCUS a Small Cap stock.
How many employees does ARCUS BIOSCIENCES INC have?
ARCUS BIOSCIENCES INC (RCUS) currently has 577 employees.
What are the support and resistance levels for ARCUS BIOSCIENCES INC (RCUS) stock?
ARCUS BIOSCIENCES INC (RCUS) has a resistance level at 9.13. Check the full technical report for a detailed analysis of RCUS support and resistance levels.
Is ARCUS BIOSCIENCES INC (RCUS) expected to grow?
The Revenue of ARCUS BIOSCIENCES INC (RCUS) is expected to decline by -43.09% in the next year. Check the estimates tab for more information on the RCUS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ARCUS BIOSCIENCES INC (RCUS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RCUS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RCUS, evaluating the profitability, health, valuation and growth aspects
- ARCUS BIOSCIENCES INC (RCUS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ARCUS BIOSCIENCES INC (RCUS) Sales and EPS estimates to see what analysts future expectations are.
- ARCUS BIOSCIENCES INC (RCUS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ARCUS BIOSCIENCES INC (RCUS) Insider and Institutional Ownership to learn about the owners and their transactions.
- ARCUS BIOSCIENCES INC (RCUS) Stock Chart to make your own analysis
- ARCUS BIOSCIENCES INC (RCUS) Latest news and press-releases to stay up to date.
Does ARCUS BIOSCIENCES INC (RCUS) stock pay dividends?
RCUS does not pay a dividend.
When does ARCUS BIOSCIENCES INC (RCUS) report earnings?
ARCUS BIOSCIENCES INC (RCUS) will report earnings on 2025-05-06, after the market close.
What is the Price/Earnings (PE) ratio of ARCUS BIOSCIENCES INC (RCUS)?
ARCUS BIOSCIENCES INC (RCUS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.1).
What is the Short Interest ratio of ARCUS BIOSCIENCES INC (RCUS) stock?
The outstanding short interest for ARCUS BIOSCIENCES INC (RCUS) is 9.65% of its float. Check the ownership tab for more information on the RCUS short interest.
RCUS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RCUS. When comparing the yearly performance of all stocks, RCUS is a bad performer in the overall market: 88.17% of all stocks are doing better.
RCUS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RCUS. RCUS may be in some trouble as it scores bad on both profitability and health.
RCUS Financial Highlights
Over the last trailing twelve months RCUS reported a non-GAAP Earnings per Share(EPS) of -3.1. The EPS increased by 25.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.61% | ||
| ROE | -58.35% | ||
| Debt/Equity | 0.1 |
RCUS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to RCUS. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of -37.9% and a revenue growth -43.09% for RCUS